White background with no visible content or imagery.

Regulatory Writing

Regulatory writing is a discipline that sits at the intersection of science, medicine and law. The documents it produces, from clinical trial applications to marketing authorisation dossiers, determine whether a product can enter clinical development and, ultimately, whether it reaches the patients who need it.

At Niche, our regulatory writers combine deep scientific knowledge with a precise, structured approach to document preparation that meets the exacting standards of agencies on both sides of the Atlantic.
Get In Touch
"I have found the Niche team to be knowledgeable and professional in approach, executing new work in a skilled manner and within required timelines."
Geoff Down
Director, Clinical Pharmacology and Discovery Medicine

GlaxoSmithKline

What We Do

We prepare regulatory documents for all stages of clinical development, from first applications to conduct studies in humans through to the complex integrated summaries that form the core of a marketing authorisation application. Our team has experience working with the MHRA, EMA and FDA, and understands the differences in expectation and preference between them. 

Regulatory writing is not simply a matter of presenting data clearly, though clarity matters enormously. It also requires an understanding of the regulatory strategy behind a programme, so that documents are positioned appropriately within the broader context of the submission and the agency relationship.

Circular diagram showing comprehensive documentation solutions for clinical development, with eight connected elements including clinical protocols, study reports, and safety updates.

How We Work

We work from the data and study documentation that the sponsor provides, which means our involvement is typically most effective when we are engaged early in the process. We review source documents thoroughly, ask the questions that need to be asked, and flag any gaps or inconsistencies before they become problems in submission. 

Review cycles are structured and transparent. We produce clean, and tracked drafts that allow the sponsor's medical and scientific teams to engage efficiently with the content, and we manage the revision process to agreed timelines.

Scope Of Service 

  • Clinical Trial Authorisation applications (UK and EU) 
  • Investigational New Drug applications (US) 
  • Investigator’s brochures and updates 
  • Clinical study reports (ICH E3 compliant) 
  • Integrated summaries of safety 
  • Integrated summaries of efficacy 
  • New Drug Application and Marketing Authorisation Application modules 
  • Benefit-risk assessments 
  • Paediatric Investigation Plan submissions 
  • Orphan designation applications 
  • Scientific advice briefing documents 
  • Responses to agency questions and deficiency letters
Download our services guide 
Frequently Asked Questions
ICH E3 is the international guideline that defines the structure and content of clinical study reports submitted to regulatory authorities. Compliance with this guideline means that the report follows the specified format, covers all required content areas, and presents the data in a way that allows regulators to assess the conduct and results of the study. Most major regulatory agencies, including the MHRA, EMA and FDA, expect study reports to follow this format.
That depends significantly on the study complexity, the source data quality and completeness, and the number of review cycles required. A straightforward Phase I study report might take six to eight weeks from final data (tables, figures and listings) to final version. A complex Phase III study report could take considerably longer. We agree timelines with sponsors at the outset and manage the process proactively to meet them.
Yes. The UK's departure from the European Union created a divergentce in regulatory pathways that affects how certain submissions are structured and where they are directed. We have experience preparing documents for both the MHRA and the EMA, and we understand the practical implications of submitting to both in parallel or sequentially.

Case Histories

Get our latest news and publications

Sign up to our news letter

© 2025 Niche.org.uk     All rights reserved

HomePrivacy policy Corporate Social Responsibility
chevron-down